Logo Image
Opinion|Videos|November 27, 2024

Emerging Horizons in HER2-Directed NSCLC Treatments

Key Takeaways

  • Recent trials, including SOHO-01, inetetamab/pyrotinib, and BEAMION Lung 01, show promising results for HER2-directed therapies in NSCLC.
  • Advancements in targeting HER2 mutations suggest potential improvements in treatment efficacy and patient outcomes.
SHOW MORE

A review of recent clinical trial results for emerging HER2-directed therapies, including SOHO-01, inetetamab/pyrotinib, and BEAMION Lung-01, and their potential impact on the future treatment landscape for HER2-positive NSCLC.

Episodes in this series

Video content above is prompted by the following:

  • Several HER2-directed therapies are currently in development. Could you discuss the recent clinical trial results for emerging agents, such as those from the SOHO-01, the inetetamab/pyrotinib combination study, and the BEAMION Lung 01 data and what implications might these findings have for the future landscape of HER2-directed therapies in NSCLC?

Related Content